
    
      A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics
      and Preliminary Anti-tumour Activity of Ascending Doses of AZD9496 in Women with Estrogen
      Receptor Positive HER-2 Negative Advanced Breast Cancer
    
  